[Alprostadil for nonrevascularizable critical lower limb ischemia]
Donato M, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001393
Spanish
Original Title:
Alprostadil para isquemia crítica de miembros inferiores no revascularizable
Authors' recommendations:
CONCLUSIONS
No evidence comparing alprostadil with other prostanoids or other treatment alternatives for the management of patients with non-revascularizable critical lower limb ischemia has been found.
Moderate quality evidence indicates that this technology does not offer any advantage over placebo in the condition described when assessing pain relief at rest, decrease in analgesic use, necrosis and ulcer healing and major amputation. Its use could be associated to a higher rate of adverse events. The identified studies only had short-term follow up.
The clinical practice guidelines surveyed are contradictory in their recommendations on the use of prostanoids for critical limb ischemia. The Argentina´s Unique Reimbursement Program covers it for the assessed indication.
Several regulatory agencies, such as the United States or European ones, do not authorize alprostadil for this indication, although Argentina´s National Administration of Drugs, Foods and Medical Devices does (ANMAT).
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Ischemia
- Limb Salvage
- Lower Extremity
- Alprostadil
- Vasodilator Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.